Intra-Cellular Therapies Inc (NASDAQ: ITCI) has reported E.P.S. of $-0.16 for its fourth fiscal quarter (ending December 31) versus $-0.30 for the same period a year ago — a decline of -47%. For the latest four quarters through December 31, E.P.S. were $-0.72 compared to $-1.46 a year ago — a decline of -51%.
Recent Price Action
Intra-Cellular Therapies Inc (NASDAQ: ITCI) stock closed at $128.60 on 2/21/25 after a slight gain of 0.05%. However, this advance was accompanied by exceptionally low trading volume at 38% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and is unchanged during the last week.
Current PriceTarget Research Rating
Intra-Cellular Therapies has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Intra-Cellular Therapies has a very low Appreciation Score of 8 but a good Power Rating of 82, triggering the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment